TrialDrug design, development and therapy2012

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.

Georg Golor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.